Payne Capital LLC Invests $508,000 in Amgen Inc. $AMGN

Payne Capital LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 1,800 shares of the medical research company’s stock, valued at approximately $508,000.

Other hedge funds have also added to or reduced their stakes in the company. Legacy Investment Solutions LLC acquired a new stake in shares of Amgen during the 2nd quarter worth about $27,000. Evelyn Partners Investment Management LLP bought a new position in Amgen in the 2nd quarter valued at about $32,000. Howard Hughes Medical Institute acquired a new stake in Amgen during the second quarter worth approximately $32,000. Quaker Wealth Management LLC lifted its position in Amgen by 200.0% during the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock worth $34,000 after acquiring an additional 240 shares during the last quarter. Finally, Cloud Capital Management LLC bought a new stake in shares of Amgen during the third quarter worth approximately $34,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares in the company, valued at $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the sale, the senior vice president directly owned 7,082 shares in the company, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 10,908 shares of company stock valued at $3,674,966. Company insiders own 0.69% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN opened at $338.59 on Wednesday. The company has a market cap of $182.32 billion, a price-to-earnings ratio of 26.17, a PEG ratio of 3.03 and a beta of 0.46. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $353.25. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. The stock has a fifty day moving average price of $332.76 and a 200-day moving average price of $310.04.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The company had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter last year, the business earned $5.31 earnings per share. Amgen’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Friday, February 13th. This is a boost from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is presently 73.57%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 results beat expectations — Amgen reported $5.29 EPS vs. consensus $4.76 and revenue of $9.87B vs. $9.46B; revenue rose ~8.6% YoY, driven by higher drug volumes. AMGEN Reports Fourth Quarter and Full Year 2025 Financial Results (Press Release/Slides)
• Positive Sentiment: Analysts and media note the quarter beat Street estimates on higher sales and a lower effective tax rate — items that helped EPS performance. Reuters: Amgen quarterly results beat Street estimates
• Neutral Sentiment: FY‑2026 guidance was reiterated/updated to an EPS range of 21.600–23.000 and revenue guidance roughly $37.0B–$38.4B; the range overlaps consensus but is wide, which may leave investors wanting clearer directional guidance.
• Neutral Sentiment: Market commentary and conference coverage remain generally constructive on Amgen’s pipeline and longer‑term prospects (e.g., positive remarks from commentators at the JPMorgan Healthcare Conference), supporting medium‑term fundamentals. Jim Cramer / Pipeline Commentary
• Negative Sentiment: Some of the reported earnings strength reflected lower net unrealized losses on equity investments and a lighter tax burden rather than pure operational margin expansion; that can temper how investors value the beat relative to recurring cash‑earnings. WSJ: Amgen logs higher Q4 revenue, lower unrealized losses
• Negative Sentiment: Broader market dynamics — rotation out of certain sectors and post‑earnings profit‑taking — likely amplified the selloff despite the beat; trading volumes were elevated on the move. Zacks: Markets rotate back out of tech after Q4 earnings

Wall Street Analyst Weigh In

AMGN has been the topic of a number of recent research reports. Oppenheimer set a $400.00 target price on Amgen and gave the stock an “outperform” rating in a research note on Thursday, January 29th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. Scotiabank initiated coverage on Amgen in a report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 target price for the company. Daiwa Capital Markets boosted their target price on shares of Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, November 18th. Finally, Royal Bank Of Canada upped their price target on shares of Amgen from $330.00 to $335.00 and gave the company an “outperform” rating in a research note on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $342.45.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.